Get the Stockscreener App
35.10
9.04%
2.91
Rapt Therapeutics Inc stock is traded at $35.10, with a volume of 424.35K.
It is up +9.04% in the last 24 hours and up +3.14% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$32.19
Open:
$32.01
24h Volume:
424.35K
Relative Volume:
0.87
Market Cap:
$972.65M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-11.51
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
+4.40%
1M Performance:
+3.14%
6M Performance:
+233.65%
1Y Performance:
+268.70%
1-Day Range:
$32.00
$35.47
1-Week Range:
$32.00
$35.47
52-Week Range:
$5.6652
$42.39
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
35.10 | 892.01M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-20-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-26-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Breakout Zone: Should I set a stop loss on Volcon IncJuly 2025 Short Interest & High Return Trade Guides - baoquankhu1.vn
Rapt Therapeutics (NASDAQ:RAPT) Trading Down 6.8%What's Next? - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Short Interest Update - MarketBeat
RAPT: Ozureprobart advances with strong phase 2 data, targeting broad allergic disorders and unmet needs - TradingView — Track All Markets
RAPT: Ozureprobart advances with less frequent dosing and broader efficacy, targeting major allergic disorders - TradingView — Track All Markets
RAPT Therapeutics, Inc. Announces Participation in JPM Healthcare Conference - TradingView — Track All Markets
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Rapt Therapeutics (NASDAQ:RAPT) Shares Gap Up – Time to Buy? - Defense World
Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated at Piper Sandler - Defense World
Published on: 2026-01-11 11:16:12 - Улправда
Piper Sandler Initiates RAPT Therapeutics(RAPT.US) With Buy Rating, Announces Target Price $95 - 富途牛牛
Published on: 2026-01-11 01:06:13 - Улправда
Will RAPT Therapeutics Inc. stock maintain dividend yield2025 Market Trends & Reliable Intraday Trade Alerts - Улправда
How RAPT Therapeutics Inc. stock benefits from global expansionQuarterly Portfolio Report & Risk Adjusted Swing Trade Ideas - Улправда
Rapt Therapeutics (NASDAQ:RAPT) Upgraded to "Strong-Buy" at Piper Sandler - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Shares Gap UpTime to Buy? - MarketBeat
Piper Sandler initiates coverage on Rapt Therapeutics stock with Overweight rating - Investing.com Canada
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Will RAPT Therapeutics Inc. (0RA0) stock benefit from Fed rate cutsMarket Sentiment Review & Low Volatility Stock Suggestions - Улправда
RAPT Therapeutics, Inc.Common Stock (NQ: RAPT - FinancialContent
RAPT Therapeutics to Present Company Overview at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Rapt Therapeutics (NASDAQ:RAPT) Shares Up 7%Time to Buy? - MarketBeat
User | malvern-online.comRAPT Therapeutics, Inc.Common Stock (Nasdaq:RAPT) Stock Quote - FinancialContent
Rapt Therapeutics (NASDAQ:RAPT) Trading Down 4%Should You Sell? - MarketBeat
Can RAPT Therapeutics Inc. stock sustain institutional interestSupport and Resistance Levels & Budget Friendly Trading Ideas - bollywoodhelpline.com
RAPT Therapeutics (RAPT) Is Up 8.0% After Index Additions And Trial Progress News Has The Bull Case Changed? - simplywall.st
RAPT Therapeutics (RAPT) Joins Key Biotech Index Is Its Investor Story Entering a New Phase? - Yahoo Finance
Rapt Therapeutics (NASDAQ:RAPT) Trading 9.8% HigherWhat's Next? - MarketBeat
RAPT Therapeutics, Inc.(NasdaqGM:RAPT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Can RAPT Therapeutics Inc. (0RA0) stock resist broad market declinesQuarterly Growth Report & Safe Entry Zone Identification - Улправда
TD Cowen Initiates Coverage on RAPT Therapeutics (RAPT) with a “Buy” - Insider Monkey
TD Cowen Initiates Coverage on RAPT Therapeutics (RAPT) with a "Buy" - Finviz
Certain Pre Funded warrants of RAPT Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2025. - marketscreener.com
Certain Options of RAPT Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2025. - marketscreener.com
Certain Common Stock of RAPT Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2025. - marketscreener.com
Is RAPT Therapeutics Inc. (0RA) stock a top dividend aristocrat candidateRisk Management & Free Daily Entry Point Trade Alerts - Улправда
Will RAPT Therapeutics Inc. stock outperform value stocksJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
12 Best Multibagger Stocks to Buy Heading into 2026 - Insider Monkey
Will RAPT Therapeutics Inc. stock deliver long term returnsJuly 2025 Trends & Free Community Consensus Stock Picks - Улправда
Is RAPT Therapeutics Inc. (0RA) stock among top earnings playsMarket Performance Summary & Stepwise Swing Trade Plans - ulpravda.ru
Rapt Therapeutics (NASDAQ:RAPT) Now Covered by TD Cowen - Defense World
Published on: 2025-12-19 09:56:31 - Улправда
Published on: 2025-12-19 01:07:45 - Улправда
Why analysts maintain buy rating on RAPT Therapeutics Inc. (0RA0) stockInsider Buying & Accurate Buy Signal Alerts - Улправда
TD Cowen Initiates Coverage on RAPT Therapeutics With Buy Rating - marketscreener.com
Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated at TD Cowen - MarketBeat
TD Cowen initiates coverage on Rapt Therapeutics stock with Buy rating - Investing.com Canada
Rapt Therapeutics (NASDAQ:RAPT) Stock Price Down 9.2%Should You Sell? - MarketBeat
RAPT Therapeutics, Inc. (NASDAQ:RAPT) surges 5.3%; individual investors who own 34% shares profited along with institutions - Yahoo Finance
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):